|
1) Katritsis DG, Ioannidis JPA. Percutaneous coronary intervention versus conservative therapy in nonacute coronay artery disease: A meta-analysis. Circulation. 2005; 111: 2906-12
|
|
|
|
2) Boden WE, OʼRourke RA, Teo KK, et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356: 1506-16
|
|
|
|
|
|
3) BARI 2D Study Group, Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009 Jun 11; 360: 2503-15
|
|
|
|
|
|
4) Chaitman BR, Hardison RM, Adler D, et al. By-pass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation. 2009; 120: 2529-40
|
|
|
|
|
|
5) Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: Comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009; 119: 3198-206
|
|
|
|
|
|
6) Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, et al. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet. 2009; 373: 911-8
|
|
|
|
|
|
7) Yusuf S, Zucker D, Peduzzi, P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomized trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994; 344: 563-70
|
|
|
|
|
|
8) Hannan EL, Wu C, Walford G, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N Engl J Med. 2008; 358: 331-41
|
|
|
|
|
|
9) Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol. 2010; 55: 432-40
|
|
|
|
|
|
10) Serruys PW, Morice MC, Kappetein AP, et al; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009; 360: 961-72
|
|
|
|
|
|
11) Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multi-vessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. 2009; 373: 1190-7
|
|
|
|
|
|
12) Kimura T, Morimoto T, Furukawa Y, et al. Long-term outcomes of coronary-artery bypass graft surgery versus percutaneous coronary intervention for multivessel coronary artery disease in the bare-metal stent era. Circulation. 2008; 118 Suppl: S199-209
|
|
|
|
|
|
13) Patel MR, Dehmer GJ, Hirshfeld JW, et al. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: A Report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardio-vascular Computed Tomography. Circulation. 2009; 119: 1330-52
|
|
|
|
|
|
14) Kushner FG, Hand M, Smith SC Jr, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009; 120: 2271-306
|
|
|
|
|
|
15) Krempf M, Parhofer KG, Steg PG, et al; Reach Registry Investigators. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis(from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol. 2010; 105: 667-71
|
|
|
|
|
|
16) 堀田 饒, 中村二郎, 岩本安彦, 他. アンケート調査による日本人糖尿病の死因 1991～2000年の10年間, 18, 385名での検討. 糖尿病. 2007; 50: 46-61
|
|
|
|
|
|
17) 大野貴之, 髙本眞一, 川島 大, 他. ミニレビュー糖尿病網膜症と冠動脈疾患. 糖尿病. 2009; 52: 935-9
|
|
|
|
|
18) Ohno T, Takamoto S, Motomura N. Diabetic retinopathy and coronary artery disease: From the cardiac surgeonʼs perspective. Ann Thorac Surg. 2008; 85: 681-9
|
|
|
|
|
|
19) Ohno T, Kinoshita O, Fujita H, et al. Detecting occult coronary artery disease followed by early coronary artery bypass surgery in patients with diabetic retinopathy: Report from a diabetic retinocoronary clinic. J Thorac Cardiovas Surg. 2010; 139: 92-7
|
|
|
|
|
|
20) Ohno T, Kobayashi J, Sasako Y, et al. The impact of diabetic retinopathy on long-term outcome following coronary artery bypass graft surgery. J Am Coll Cardiol. 2002; 40: 428-436
|
|
|
|
|
|
21) Ohno T, Ando J, Ono M, et al. The beneficial effect of coronary-artery-bypass surgery on survival in patients with diabetic retinopathy. Eur J Cardiothorac Surg. 2006; 30: 881-6
|
|
|
|
|
|
22) Hlatky MA, Rogers WJ, Johnstone I, et al. Medical care costs and quality of life after randomization to coronary angioplasty or coro-nary bypass surgery. N Engl J Med. 1977; 336: 92-9
|
|
|
|
|
|
23) Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomized Basel Stent Kosten Effektivitats Trial (BASKET). Lancet. 2005; 366: 921-9
|
|
|
|
|
|
24) Hisagi M, Ohno T, Takamoto S, et al. Medical costs during 2 years after CABG or DES implantation for stable coronary disease in non-diabetic patients. J Cardiol Jpn Ed. 2009; 3: 113-7
|
|
|
|
|
|
25) Shimizu T, Ohno T, Ando J, et al. Mid-term results and costs of coronary artery bypass vs drug-eluting stents for unprotected left main coronary artery disease. Circ J. 2010; 74: 426-7
|
|
|
|
|